Skip to main content
Signal8

BIOGEN INC. (BIIB) Form 8-K — Jul 1, 2026

$BIIBForm 8-KItems 2.02Filed Jul 1, 2026, 4:08 PM ET0000875045-26-000068Original filing

Biogen issued a preliminary estimate regarding its financial results for the second and third quarters of 2026, citing significant expenses related to acquired in-process research and development. The company expects a pre-tax charge of approximately $164 million in the second quarter, which is projected to negatively impact both GAAP and non-GAAP net income per diluted share by about $0.95.

Key figures

Q2 2026 eps impact
$0.95
Q2 2026 iprd expense
$164 million
Q3 2026 eps impact range
$1.75 - $1.95
Q3 2026 iprd expense range
$290 million - $320 million

Price after filing

1 day: +3.0%7 days: -4.5%30 days: -0.2%

Close on the filing date to close N calendar days later (from $209.74). Historical, not a forecast.

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.